Q4 EPS Estimates for Sanara MedTech Decreased by Analyst

Sanara MedTech Inc. (NASDAQ:SMTI) – HC Wainwright cut their Q4 2026 earnings per share estimates for Sanara MedTech in a report issued on Thursday, April 2nd. HC Wainwright analyst Y. Chen now anticipates that the company will earn $0.12 per share for the quarter, down from their previous forecast of $0.19. HC Wainwright currently has a “Buy” rating and a $36.00 price objective on the stock. The consensus estimate for Sanara MedTech’s current full-year earnings is ($1.10) per share.

A number of other equities research analysts also recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sanara MedTech in a research note on Thursday, January 22nd. Zacks Research lowered shares of Sanara MedTech from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 20th. Finally, Wall Street Zen raised shares of Sanara MedTech from a “hold” rating to a “buy” rating in a report on Saturday, March 28th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $36.00.

Sanara MedTech Trading Down 0.1%

Sanara MedTech stock opened at $17.24 on Friday. The stock has a market cap of $158.09 million, a P/E ratio of -4.08 and a beta of 1.10. The company has a debt-to-equity ratio of 7.75, a quick ratio of 1.59 and a current ratio of 1.80. The firm’s fifty day moving average price is $19.58 and its 200-day moving average price is $23.96. Sanara MedTech has a fifty-two week low of $16.05 and a fifty-two week high of $35.95.

Sanara MedTech (NASDAQ:SMTI) last announced its quarterly earnings results on Tuesday, March 24th. The company reported $0.04 earnings per share for the quarter, missing the consensus estimate of $0.11 by ($0.07). The company had revenue of $27.55 million during the quarter, compared to analysts’ expectations of $27.90 million. Sanara MedTech had a negative net margin of 36.42% and a negative return on equity of 20.73%.

Hedge Funds Weigh In On Sanara MedTech

Large investors have recently modified their holdings of the company. Stonebridge Wealth Management LLC bought a new position in Sanara MedTech during the second quarter valued at approximately $3,397,000. Squarepoint Ops LLC lifted its holdings in shares of Sanara MedTech by 56.0% in the 4th quarter. Squarepoint Ops LLC now owns 48,953 shares of the company’s stock worth $1,143,000 after acquiring an additional 17,570 shares during the last quarter. Hsbc Holdings PLC bought a new stake in shares of Sanara MedTech in the 2nd quarter worth approximately $382,000. Jane Street Group LLC purchased a new stake in shares of Sanara MedTech in the 4th quarter valued at $355,000. Finally, NewEdge Advisors LLC bought a new position in shares of Sanara MedTech during the 4th quarter valued at $243,000. 8.10% of the stock is owned by hedge funds and other institutional investors.

Sanara MedTech Company Profile

Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company’s core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.

With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies.